This content is from: Patents
Federal Circuit reverses Section 101 invalidation of life science patent
The Federal Circuit has ruled that the claims of a patent for liver cell treatment were not directed to a patent-ineligible concept, in a decision that provides guidance on how life science innovations can satisfy the Mayo test
To access our in-house intelligence please request a trial here.
Read this article – and more – for a 30 day period.
REQUEST ACCESSAre you already an Managing IP subscriber? Login here